We are delighted to have supported Genflow Biosciences Plc on their Admission to the Main Market of the London Stock Exchange.
Genflow Biosciences Plc has raised gross proceeds of £3.7 million through the issue of 47,036,500 Ordinary Shares priced at 8p each, giving a market capitalisation of £23.4 million on Admission.
Genflow Biosciences Plc is a biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age.
“We are proud to be the first pure play longevity firm to list in Europe, on the London Stock Exchange. The longevity sector has seen strong growth in recent years, mainly driven by advances in science and a better understanding of the biology of aging.
The longevity field is set to become not only a billion-dollar industry but a dominant force in the life sciences sector. We have confidence that Genflow Biosciences can both generate value for the investors and make a real difference in people’s lives.” Eric Leire, CEO | Genflow Biosciences Plc
PKF acted as reporting accountant on the transaction and the Capital Markets team included Adam Humphreys and Sam Bradshaw.